Amgen ’s EBBINGHAUS trial of Repatha shows favourable outcome

Amgen has reported a favourable cognitive function outcome from Phase III EBBINGHAUS clinical trial of Repatha (evolocumab) currently being developed to minimise low-density lipoprotein (LDL) levels.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news